Gilenya: Phase IIa start

In May, the ALS Therapy Development Institute will begin a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate 0.5 mg oral Gilenya fingolimod once daily for about 28 days in about 30 A...